Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist

Thrombosis Research

Volumn 82, Issue 6, 1996, Pages 495-507

  Bostwick, Jeffrey S ^a   Kasiewski, Charles J ^a   Chu, Valeria ^a   Klein, Scott I ^a   Sabatino, Ralph D ^a   Perrone, Mark H ^a   Dunwiddie, Christopher T ^a   Cook, Jacquelynn J ^a,b   Leadley Jr , Robert J ^a  

^a SANOFI   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antagonist; Fibrinogen; Glycoprotein; GPIIb IIIa; Platelet

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ANTICOAGULANT AGENT; COLLAGEN; FIBRINOGEN RECEPTOR ANTAGONIST; RG 13965; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; HAMSTER; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS;

EID: 0030585733     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(96)00100-4     Document Type: Article

References (31)

1. 1. FUSTER V, BADIMON L, BADIMON JJ, and CHESEBRO JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med 326, 242-250, 1992.
2. 2. MARGUERJE GA, PLOW EF, EDINGTON TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 254, 5357-5363, 1979.
3. 3 LUCCHESSI BR. ROTE WE, DRISCOLL EM, and MU D-X. Prevention of thrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist Br J Pharmacol 113, 1333-1343, 1994.
4. 2 fragment. J Card Pharmacol 23, 194-202, 1994.
5. 5 ROTE WE, WERNS SW, DAVIS JH, FEIGEN LP, KILGORE KS, and LUCCHESI BR. Plazel GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and restenosis in the canine cai artery. Cardiovasc Res 27, 500-507, 1993.
6. 6. SONG A, SCARBOROUGH RM, PHILLIPS DR, ADELMAN B, and STRONY J. Integrelin enhances fibrinolysis and prevents acute arterial reocclusion following thrombolysis in a canine anodal current model with high-grade stenosis. Circulation 86 [Suppl I], I-410. Abstract, 1992.
7. 7. THE EPIC INVESTIGATORS. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330; 956-961, 1994.
8. 8. TOPOL EF, CALIFF RM, WEISMAN HF, ELLlS SG, TCHENG JE, WORLEY S, IVANHOE R, GEORGE BS, FINTEL D, WESTON M, SIGMON K, ANDERSON KM, LEE KL, and WILLERSON JT, ON BEHALF OF THE EPIC INVESTIGATORS. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343, 881-886, 1994.
9. 9 PLOW EF, PEIRSCHBACHER MD, RUOSLAHTI E, MARGUERIE GA, GINSBERG MH. The effect of Arg-Gly-Asp-contaming peptides on fibrinogen and von Willebrand factor binding to platelets Proc Natl Acad Sci USA 82, 8057-8061, 1985.
10. 10 TCHENG JE, HARRINGTON RA, KOTTKE-MARCHANT K, KLEIMAN NS, ELLIS SG, KEREIAKES DJ, MICK MJ, NAVETTA FI, SMITH JE, WORLEY SJ, MILLER JA, JOSEPH DM, SIGMON KN, KITT MM, DU MEE CP, CALIFF RM, and TOPOL EJ, FOR THE IMPACT INVESTIGATORS. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 91, 2151-2157, 1995.
11. 11. HAWIGER J, and TIMMONS S. Binding of fibrinogen and von Willibrand Factor to platelet glycoprotein IIb-IIIa Complex. In: Methods in Enzymology, Volume 215, Platelets: Receptors, Adhesion, Secretion, Part B. Hawiger J(ed.), pp 228-243, Academic Press, San Diego, CA (1992).
12. 32. GRINNELL F, HAYS DG, and MINTER D. Cell adhesion and spreading factor. Partial purification and properties. Exp Cell Res 110, 175-190, 1977.
13. 33. RUOSLAHTI E, and ENGVALL E. Two active sites with different characters in fibronectin. FEBS Lett 97, 221-224, 1979
14. 14. LANDEGREN U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface. J Immunol Methods 67, 379-388, 1984.
15. 15. PRIOR CP, CHU V, CAMBOU B, DENT JA, EBERT B, GORE R, HOLT J, IRISH T, LEE T, MITSCHELEN J, MCCLINTOCK RA, SEARFOSS G, RICCA GA, TARR C, WEBER D, WARE J, RUGGERI ZM, and HRINDA M. Optimization of a recombinant von Willebrand Factor fragment as an antagonist of the platelet glycoprotein Ib receptor. Bio/Tech 11, 709-713, 1993.
16. 16 RUGGERI ZM, DEMARCO L, GATTI L, BADES R, and MONTGOMERY RR. Platelets have more than one binding site for von Willebrand factor. J Clin Invest 72, 1-12, 1983.
17. 17 DIMINNO G, and SILVER MJ. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potential of antithrombotic activity by ethyl alcohol. J Pharm Exp Ther 225, 57-60, 1983.
18. 18. COOK JJ, HUANG T-F, RUCINSKI B, STRZYZEWSKI M, TUMA RF, WILLIAMS JA, and NIEWIAROWSKI S. Inhibition of platelet hemostatic plug formation by trigramin, a novel RGD-peptide. Am J Physiol 256, H1038-H1043, 1989.
19. 19. FOLTS J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 83 [Suppl IV] IV3-IV14, 1991.
20. 20. RAMJIT DR, LYNCH JJ JR, SITKO GR, MELLOTT MJ, HOLAHAN MA, STABILITO II, STRANIERI MT, ZHANG G, LYNCH RJ, MANNO PD, CHANG CT-C, NUTT RP, BRADY SF, VEBER DF, ANDERSON PS, SHEBUSKI RJ, FRIEDMAN PA, and GOULD RJ Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis. J Pharm Exp Ther 266, 1501-1511, 1993.
21. 21. GOLD HK, COLLER BS, YASUDA T, SAITO T, FALLON JT, GUERRERO JL, LEINBACH RC, ZISKIND AA, and COLLEN D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 77, 670-677, 1988.
22. 22 LU HR, GOLD HK, WU Z, YASUDA T, PAUWELS P, RAPOLD HJ, NAPIER M, BUNTING S, and COLLEN D. G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs. Thromb Haemostasis 67, 686-691, 1992.
23. 23. TSCHOPP JF, DRISCOLL EM, MU D-X, BLACK SC, PIERSCHBACHER MD, and LUCCHESI BR. Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time. Coronary Artery Disease 4, 809-817, 1993.
24. 24. COLLEN D, LU HR, STASSEN J-M, VREYS I, YASUDA T, BUNTING S, and GOLD H Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemostasis 71, 95-102, 1994.
25. 25. BERNARDI MM, CALIFF RM, KLEIMAN N, ELLIS SG, and TOPOL EJ, FOR THE TAMI STUDY GROUP. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. Am J Cardiol 72, 1121-1125, 1993.
26. 26. NICHOLS AJ, VASKO JA, KOSTER PF, VALOCIK RE, RHODES GR, MILLER-STEIN C, BOPPANA V, and SAMANEN JM. The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760. J Pharm Exp Ther 270, 614-621, 1994.
27. 27. LYNCH JJ, COOK JJ, SITKO GR, HOLAHAN MA, RAMJIT DR, MELLOTT MJ, STRANIERI MT, STABILITO II, ZHANG G, LYNCH RJ, MONNO PD, CHANG CT-C, EGBERTSON MS, HALCZENKO W, DUGGAN ME, LASWELL WL, VASSALLO LM, SHAFER JA, ANDERSON PS, FRIEDMAN PA, HARTMAN GD, and GOULD RJ. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharm Exp Ther 272, 20-32, 1995
28. 28 PANZER-KNODLE S, TAITE BB, MEHROTRA DV, NICHOLSON NS, and FEIGEN LP. Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation. J Pharm Tox Meth 30, 47-53, 1993.
29. 29 COOK NS, ZERWES H-G, TAPPARELLI C, POWLING M, SINGH J, METTERNICH R, and HAGENBACH A. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists. Thromb Haemostasis 70,531-539, 1993.
30. 30. COOK NS, BRUTTGER O, PALLY C, and HAGENBACH A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in Guinea-pigs and dogs: Evidence that Ro 43-8857 is orally active. Thromb Haemostasis 70, 838-847, 1993.
31. 31. COX D, MOTOYAMA Y, SEKI J, AOKI T, DOHI M, and YOSHIDA K. Pentamadine: A non-peptide GPIIb/IIIa antagonist - in vitro studies on platelets from humans and other species. Thromb Haemostasis 68, 731-736, 1992.